Guiding clinicians to recognize toxicity levels of newer immunotherapy agents

Guiding clinicians to recognize toxicity levels of newer immunotherapy agents

VJOncology

1 year
171 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
The unique side effects that accompany the use of immune checkpoint inhibitors for the treatment of cancer need to be closely monitored to ensure the highest quality of patient care. Here, Christopher Campen, PharmD, BCOP, from the GHS Cancer Institute, Greenville, SC, explains how new collaborative guidelines from the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) have been developed to help healthcare providers assess and manage these side effects. This interview was recorded at the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO.
Up Next Autoplay
Light-to-Moderate Exercise May Provide Sickle Cell Disease Benefits
Light-to-Moderate Exercise May Provide Sickle Cell Disease Benefits
Category: News
1 Views
Cancer-News 57 minutes
Renal Case Presentations
Renal Case Presentations
Category: Kidney Cancer
5 Views
kidneycancer 19 hours
Radiation to Prime the Immune System
Radiation to Prime the Immune System
Category: Kidney Cancer
4 Views
kidneycancer 20 hours
ProVent Trial: When Will There Be Results?
ProVent Trial: When Will There Be Results?
Category: Prostate Cancer
3 Views
CURC 22 hours
How is Immunotherapy Used in Prostate Cancer? @UrologyUS
How is Immunotherapy Used in Prostate Cancer? @UrologyUS
Category: Prostate Cancer
3 Views
CURC 22 hours
ProVent Trial Changing AS Landscape @UrologyUS
ProVent Trial Changing AS Landscape @UrologyUS
Category: Prostate Cancer
3 Views
CURC 23 hours
Current Treatment Options in the ProVent Trial
Current Treatment Options in the ProVent Trial
Category: Prostate Cancer
3 Views
CURC 23 hours
Phase 3 ProVent Clinical Trial @UrologyUS
Phase 3 ProVent Clinical Trial @UrologyUS
Category: Prostate Cancer
4 Views
CURC 1 day
Loss of SETD2 is associated with dysregulation of protein translation in clear cell renal cell carcinoma
Loss of SETD2 is associated with dysregulation of protein translation in clear cell renal cell carcinoma
Category: Kidney Cancer
7 Views
kidneycancer 2 days
Immune Correlates and Prognostic Significance of CD73 Expression in Renal Cell Carcinoma
Immune Correlates and Prognostic Significance of CD73 Expression in Renal Cell Carcinoma
Category: Kidney Cancer
10 Views
kidneycancer 2 days